Login to Your Account

Clinic Roundup

Friday, January 28, 2011
Provectus Pharmaceuticals Inc., of Knoxville, Tenn., completed patient accrual and treatment of subjects in its Phase I trial of PV-10 for liver cancer. The study involved six subjects with cancer metastatic to the liver or with recurrent liver cancer, with the goal of determining the safety and tolerability of a single intralesional injection of PV-10.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription